We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Alector (ALEC) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Alector (ALEC - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Alector is a member of our Medical group, which includes 915 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Alector is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ALEC's full-year earnings has moved 120.7% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that ALEC has returned about 62.2% since the start of the calendar year. Meanwhile, stocks in the Medical group have gained about 10.4% on average. This means that Alector is performing better than its sector in terms of year-to-date returns.
Another stock in the Medical sector, CVS Health (CVS - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 12.2%.
For CVS Health, the consensus EPS estimate for the current year has increased 2.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Alector belongs to the Medical - Biomedical and Genetics industry, a group that includes 449 individual companies and currently sits at #88 in the Zacks Industry Rank. This group has gained an average of 10.2% so far this year, so ALEC is performing better in this area.
CVS Health, however, belongs to the Medical Services industry. Currently, this 70-stock industry is ranked #73. The industry has moved +9.8% so far this year.
Going forward, investors interested in Medical stocks should continue to pay close attention to Alector and CVS Health as they could maintain their solid performance.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging Alector (ALEC) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Alector (ALEC - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Alector is a member of our Medical group, which includes 915 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Alector is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ALEC's full-year earnings has moved 120.7% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that ALEC has returned about 62.2% since the start of the calendar year. Meanwhile, stocks in the Medical group have gained about 10.4% on average. This means that Alector is performing better than its sector in terms of year-to-date returns.
Another stock in the Medical sector, CVS Health (CVS - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 12.2%.
For CVS Health, the consensus EPS estimate for the current year has increased 2.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Alector belongs to the Medical - Biomedical and Genetics industry, a group that includes 449 individual companies and currently sits at #88 in the Zacks Industry Rank. This group has gained an average of 10.2% so far this year, so ALEC is performing better in this area.
CVS Health, however, belongs to the Medical Services industry. Currently, this 70-stock industry is ranked #73. The industry has moved +9.8% so far this year.
Going forward, investors interested in Medical stocks should continue to pay close attention to Alector and CVS Health as they could maintain their solid performance.